Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma

被引：5
|
作者：
Gao, Jianjun
Karam, Jose A.
Wood, Christopher G.
Matin, Surena
Ahrar, Kamran
Jonasch, Eric
Tannir, Nizar
Campell, Matthew
Ng, Chaan S.
Slack, Rebecca S.
Rao, Priya
Allison, James P.
Blando, Jorge M.
Vence, Luis M.
Basu, Sreyashi
Zhao, Hao
Chen, Tenghui
Chen, Hong
Sharma, Padmanee
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-CT083
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT083
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC).
    Gupta, Ruby
    Ornstein, Moshe Chaim
    Gul, Anita
    Allman, Kimberly D.
    Ball, Jessica
    Wood, Laura S.
    Garcia, Jorge A.
    VonMerveldt, Dendra
    Hammers, Hans J.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [42] Adverse Events Induced by Nivolumab Plus Ipilimumab vs. Nivolumab Monotherapy among Cancer Patients: A Systematic Review and Meta-Analysis
    Kamat, Shweta
    Patel, Jay
    Brown, Britny R.
    Vyas, Ami
    CANCER INVESTIGATION, 2022, 40 (09) : 777 - 788
  • [43] Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Yamashita, Shimpei
    Hamamoto, Shuzo
    Furukawa, Junya
    Fujita, Kazutoshi
    Takahashi, Masayuki
    Miyake, Makito
    Ito, Noriyuki
    Iwamoto, Hideto
    Kohjimoto, Yasuo
    Hara, Isao
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (06) : 722 - 729
  • [44] Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Hayase, T.
    Washino, S.
    Shirotake, S.
    Inoue, M.
    Kagawa, M.
    Takeshita, H.
    Miura, Y.
    Hyodo, Y.
    Izumi, K.
    Kawakami, S.
    Saito, K.
    Kageyama, Y.
    Oyama, M.
    Miyagawa, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S1488 - S1489
  • [45] Nivolumab plus cabozantinib for advanced renal cell carcinoma
    Benjamin, David J.
    Nolla, Kyle
    Cella, David
    FUTURE ONCOLOGY, 2022, 18 (39) : 4351 - 4359
  • [46] RANDOMIZED PHASE II OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (RGBM). NIVOLUMAB BENEFITS OLDER POPULATION
    Ahluwalia, Manmeet
    Peereboom, David
    Rauf, Yasmeen
    Wen, Patrick
    Reardon, David
    NEURO-ONCOLOGY, 2021, 23 : 52 - 52
  • [47] Re: Nivolumab plus Ipilimumab Versus Sunitinib in Advanced Renal-cell Carcinoma
    Powles, Tom
    EUROPEAN UROLOGY, 2018, 74 (05) : 679 - 680
  • [48] ECONOMIC EVALUATION OF NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED RENAL-CELL CARCINOMA IN JAPAN
    Maeda, T.
    Morimoto, K.
    Mo, X.
    Moriwaki, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2022, 25 (01) : S188 - S189
  • [49] Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
    Watson, Tina R.
    Gao, Xin
    Reynolds, Kerry L.
    Kong, Chung Yin
    JAMA NETWORK OPEN, 2020, 3 (10)
  • [50] GENOMIC BIOMARKERS OF RESPONSE TO NIVOLUMAB/IPILIMUMAB AND NIVOLUMAB MONOTHERAPY IN 108 PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    DiNatale, Renzo
    Lee, Chung-Han
    Chowell, Diego
    Makarov, Vladimir
    Redzematovic, Almedina
    Murray, Samuel
    Carlo, Maria
    Voss, Martin
    Coleman, Jonathan
    Russo, Paul
    Motzer, Robert
    Chan, Timothy
    Hakimi, Ari
    JOURNAL OF UROLOGY, 2019, 201 (04): : E346 - E346
12345